Search Results

There are 52754 results for: content related to: Homocysteine levels after acute levodopa intake in patients with Parkinson's disease

  1. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 27, Issue S1, June 2012, Pages: S1–S523,

    Version of Record online : 19 JUN 2012, DOI: 10.1002/mds.25051

  2. You have free access to this content
    Poster Session

    Movement Disorders

    Volume 31, Issue S2, June 2016, Pages: S1–S697,

    Version of Record online : 19 JUN 2016, DOI: 10.1002/mds.26688

  3. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 30, Issue S1, June 2015, Pages: S1–S567,

    Version of Record online : 12 JUN 2015, DOI: 10.1002/mds.26295

  4. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 29, Issue S1, May 2014, Pages: S1–S571,

    Version of Record online : 6 JUN 2014, DOI: 10.1002/mds.25914

  5. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit l-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats

    European Journal of Neuroscience

    Volume 13, Issue 1, January 2001, Pages: 162–170, Sarah A. Treseder, Sarah Rose and Peter Jenner

    Version of Record online : 20 DEC 2001, DOI: 10.1046/j.0953-816x.2000.01370.x

  6. Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: Flow-mediated dilation study

    Movement Disorders

    Volume 29, Issue 12, October 2014, Pages: 1551–1555, Jung Han Yoon, Jin Soo Lee, Seok Woo Yong, Ji Man Hong and Phil Hyu Lee

    Version of Record online : 22 AUG 2014, DOI: 10.1002/mds.26005

  7. Endogenous melatonin protects L-DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson's disease

    Journal of Pineal Research

    Volume 40, Issue 3, April 2006, Pages: 204–213, Gaia Rocchitta, Rossana Migheli, Giovanni Esposito, Bianca Marchetti, Maria S. Desole, Egidio Miele and Pier Andrea Serra

    Version of Record online : 5 DEC 2005, DOI: 10.1111/j.1600-079X.2005.00299.x

  8. You have free access to this content
    Unpredictable Rotational Responses to L-dopa in the Rat Model of Parkinson’s Disease: the Role of L-dopa Pharmacokinetics and Striatal Dopamine Depletion

    Basic & Clinical Pharmacology & Toxicology

    Volume 110, Issue 2, February 2012, Pages: 162–170, Tiina M. Kääriäinen, Mikko Käenmäki, Markus M. Forsberg, Niko Oinas, Anne Tammimäki and Pekka T. Männistö

    Version of Record online : 13 SEP 2011, DOI: 10.1111/j.1742-7843.2011.00782.x

  9. You have free access to this content
    Entacapone improves the availability of l-dopa in plasma by decreasing its peripheral metabolism independent of l-dopa/carbidopa dose

    British Journal of Clinical Pharmacology

    Volume 54, Issue 4, October 2002, Pages: 363–371, Helena Heikkinen, Anu Varhe, Tarmo Laine, Jaakko Puttonen, Marjo Kela, Seppo Kaakkola and Kari Reinikainen

    Version of Record online : 23 OCT 2002, DOI: 10.1046/j.1365-2125.2002.01654.x

  10. You have free access to this content
    Abstracts

    Movement Disorders

    Volume 32, Issue S2, June 2017, Pages: S1–S627,

    Version of Record online : 2 JUN 2017, DOI: 10.1002/mds.27087

  11. Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis

    Acta Neurologica Scandinavica

    Volume 128, Issue 2, August 2013, Pages: 73–82, X.-W. Hu, S.-M. Qin, D. Li, L.-F. Hu and C.-F. Liu

    Version of Record online : 21 FEB 2013, DOI: 10.1111/ane.12106

  12. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease

    Movement Disorders

    Volume 19, Issue 12, December 2004, Pages: 1403–1408, Padraig E. O'Suilleabhain, Teodoro Bottiglieri, Richard B. Dewey Jr., Shailja Sharma and Ramon Diaz-Arrastia

    Version of Record online : 21 JUL 2004, DOI: 10.1002/mds.20253

  13. Levodopa: Effect on cell death and the natural history of Parkinson's disease

    Movement Disorders

    Volume 30, Issue 1, January 2015, Pages: 37–44, C. Warren Olanow

    Version of Record online : 11 DEC 2014, DOI: 10.1002/mds.26119

  14. Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats

    Journal of Neuroscience Research

    Volume 72, Issue 6, 15 June 2003, Pages: 768–780, Justin D. Oh, Karnon Chartisathian, Syed M. Ahmed and Thomas N. Chase

    Version of Record online : 25 APR 2003, DOI: 10.1002/jnr.10629

  15. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients

    Movement Disorders

    Volume 20, Issue 1, January 2005, Pages: 69–72, Paolo Lamberti, Stefano Zoccolella, Giovanni Iliceto, Elio Armenise, Angela Fraddosio, Michele De Mari and Paolo Livrea

    Version of Record online : 3 AUG 2004, DOI: 10.1002/mds.20261

  16. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: Effect of dose, frequency of administration, and brain exposure

    Movement Disorders

    Volume 18, Issue 5, May 2003, Pages: 487–495, Lance A. Smith, Michael J. Jackson, Matthew J. Hansard, Eleni Maratos and Peter Jenner

    Version of Record online : 28 MAR 2003, DOI: 10.1002/mds.10394

  17. You have free access to this content
    l-DOPA and glia-conditioned medium have additive effects on tyrosine hydroxylase expression in human catecholamine-rich neuroblastoma NB69 cells

    Journal of Neurochemistry

    Volume 78, Issue 3, August 2001, Pages: 535–545, E. Rodríguez-Martín, S. Canals, M. J. Casarejos, S. de Bernardo, A. Handler and M. A. Mena

    Version of Record online : 20 DEC 2001, DOI: 10.1046/j.1471-4159.2001.00440.x

  18. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr

    Movement Disorders

    Volume 30, Issue 1, January 2015, Pages: 19–36, Andrew J. Lees, Eduardo Tolosa and C. Warren Olanow

    Version of Record online : 8 DEC 2014, DOI: 10.1002/mds.26120

  19. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia

    Journal of Neurochemistry

    Volume 141, Issue 4, May 2017, Pages: 614–625, Andreas Dammann Andersen, Morten Blaabjerg, Michael Binzer, Akram Kamal, Helle Thagesen, Troels Wesenberg Kjaer, Egon Stenager and Jan Bert Paul Gramsbergen

    Version of Record online : 30 MAR 2017, DOI: 10.1111/jnc.13997

  20. Improving l-dopa therapy: The development of enzyme inhibitors

    Movement Disorders

    Volume 30, Issue 1, January 2015, Pages: 103–113, Oscar S. Gershanik

    Version of Record online : 21 OCT 2014, DOI: 10.1002/mds.26050